A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life

被引：19
作者：
Schiavi, M. C. [1 ]
Di Tucci, C. [1 ]
Colagiovanni, V. [1 ]
Faiano, P. [1 ]
Giannini, A. [1 ]
D'Oria, O. [1 ]
Prata, G. [1 ]
Perniola, G. [1 ]
Monti, M. [1 ]
Zullo, M. A. [2 ]
Muzii, L. [1 ]
Panici, P. Benedetti [1 ]
机构：
[1] Univ Rome Sapienza, Umberto Hosp 1, Dept Gynecol & Obstet Sci & Urol Sci, Viale Policlin 155, I-00161 Rome, Italy
[2] Univ Rome, Dept Surg Week Surg, Campus Biomed, Rome, Italy
来源：
LUTS-LOWER URINARY TRACT SYMPTOMS | 2019年 / 11卷 / 02期
关键词：
bovine colostrum; genitourinary syndrome; quality of life; sexual function; vulvovaginal atrophy; GENITOURINARY SYNDROME; MENOPAUSE; HEALTH; GEL; DRYNESS; IMPACT;
D O I：
10.1111/luts.12204
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Objective This study assessed the effectiveness and safety of a medical device containing purified bovine colostrum (Monurelle Biogel; Zambon, Bresso, Italy) in improving vulvovaginal atrophy (VVA), sexual function, urinary symptoms, and quality of life (QoL) in postmenopausal women. Methods In all, 172 postmenopausal women with VVA were included in the study. All women were treated with vaginal Monurelle Biogel daily for 12 weeks. Patients underwent clinical examinations, completed a 3-day voiding diary, and had VVA graded using the Vaginal Health Index (VHI) at baseline and 12 weeks. Patients also completed the Female Sexual Function Index (FSFI), overactive bladder questionnaire (OAB-Q), and the Urogenital Distress Inventory (UDI-6), among others. Results After 12 weeks, there were significant increases in mean (+/- SD) VHI (12.53 +/- 3.67 vs. 19.31 +/- 3.49; P < .0001), the number of patients engaging in regular sexual activity 102 (59.3%) vs. 144 (83.7%), and in the total FSFI score (21.64 +/- 2.99 vs. 28.16 +/- 1.93; P < .0001) compared with baseline. In addition, there were significant reductions in the mean number of 24-hour voids (9.57 +/- 2.12 vs. 7.13 +/- 1.22; P < .0001), urgent micturition episodes per 24 hours (1.75 +/- 0.76 vs. 1.14 +/- 0.87; P = .001), nocturia episodes (1.58 +/- 0.85 vs. 0.97 +/- 1.18; P = .0002), and urinary incontinence episodes per 24 hours (0.74 +/- 0.59 vs. 0.28 +/- 0.52; P = .003). Finally, after 12 weeks treatment, there were significant differences in UDI-6 (7.85 +/- 0.81 vs. 5.56 +/- 1.40), OAB-Q symptom (53.60 +/- 12.57 vs. 22.08 +/- 9.63), and OAB-Q health-related QoL (21.75 +/- 8.51 vs. 69.34 +/- 14.59) scores compared with baseline (P < .0001 for all). The Patient Impression of Global Improvement scale revealed global improvement in 143 women (83.14%). Conclusions Monurelle Biogel is an effective treatment for VVA in postmenopausal women, improving sexual life, urinary symptoms, and QoL.
引用
收藏
页码：O11 / O15
页数：5
相关论文
共 23 条
  • [1] Bachmann G., 1994, TREATMENT POSTMENOPA
  • [2] Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group, Clinical Trial
    Chen, Junya
    Geng, Li
    Song, Xuehong
    Li, Hongxia
    Giordan, Nicola
    Liao, Qinping
    [J]. JOURNAL OF SEXUAL MEDICINE, 2013, 10 (06) : 1575 - 1584
  • [3] Coyne K, 2000, VALUE HEALTH, V3, P141, DOI DOI 10.1016/S1098-3015(11)70554-X
  • [4] Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?
    Garrido Oyarzun, Maria Fernanda
    Castelo-Branco, Camil
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (06) : 418 - 420
  • [5] Local oestrogen for vaginal atrophy in postmenopausal women
    Lethaby, Anne
    Ayeleke, Reuben Olugbenga
    Roberts, Helen
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08):
  • [6] Monurelle Biogel® vaginal gel in the treatment of vaginal dryness in postmenopausal women
    Nappi, R. E.
    Cagnacci, A.
    Becorpi, A. M.
    Nappi, C.
    Paoletti, A. M.
    Busacca, M.
    Martella, S.
    Bellafronte, M.
    Tredici, Z.
    Di Carlo, C.
    Corda, V.
    Vignali, M.
    Bagolan, M.
    Sardina, M.
    [J]. CLIMACTERIC, 2017, 20 (05) : 467 - 475
  • [7] Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause
    Nappi, R. E.
    Palacios, S.
    [J]. CLIMACTERIC, 2014, 17 (01) : 3 - 9
  • [8] The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs
    Nappi, Rossella E.
    Palacios, Santiago
    Particco, Martire
    Panay, Nick
    [J]. MATURITAS, 2016, 91 : 81 - 90
  • [9] North Amer Menopause Soc, 2013, MENOPAUSE, V20, P888, DOI [10.1097/gme.0b013e3182a122c2, 10.1097/GME.0b013e3182a122c2]
  • [10] Treatment of the genitourinary syndrome of menopause
    Palacios, S.
    Mejia, A.
    Neyro, J. L.
    [J]. CLIMACTERIC, 2015, 18 : 23 - 29
123